Compare Stocks: MYGN, TSHA, NTLA, and IMCR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$29.71 -2.7%	$33.99	$27.56 ▼ $40.71	$1.53B	0.81	402,835 shs	657,606 shs
MYGN Myriad Genetics	$4.54 +11.8%	$3.61	$2.74 ▼ $8.59	$434.25M	1.64	2.11 million shs	2.27 million shs
NTLA Intellia Therapeutics	$12.26 +1.2%	$12.06	$7.95 ▼ $28.25	$1.72B	1.8	4.37 million shs	4.50 million shs
TSHA Taysha Gene Therapies	$4.63 -2.3%	$5.62	$3.69 ▼ $7.30	$1.51B	1.19	4.09 million shs	2.56 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	0.00%	-3.29%	-20.92%	-8.58%	-17.31%
MYGN Myriad Genetics	0.00%	+8.87%	+40.56%	-24.21%	-41.27%
NTLA Intellia Therapeutics	0.00%	+4.34%	-3.31%	-30.18%	-34.65%
TSHA Taysha Gene Therapies	0.00%	-0.86%	-16.88%	-29.10%	+45.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMCR Immunocore	$29.71 -2.7%	$33.99	$27.56 ▼ $40.71	$1.53B	0.81	402,835 shs	657,606 shs
MYGN Myriad Genetics	$4.54 +11.8%	$3.61	$2.74 ▼ $8.59	$434.25M	1.64	2.11 million shs	2.27 million shs
NTLA Intellia Therapeutics	$12.26 +1.2%	$12.06	$7.95 ▼ $28.25	$1.72B	1.8	4.37 million shs	4.50 million shs
TSHA Taysha Gene Therapies	$4.63 -2.3%	$5.62	$3.69 ▼ $7.30	$1.51B	1.19	4.09 million shs	2.56 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMCR Immunocore	0.00%	-3.29%	-20.92%	-8.58%	-17.31%
MYGN Myriad Genetics	0.00%	+8.87%	+40.56%	-24.21%	-41.27%
NTLA Intellia Therapeutics	0.00%	+4.34%	-3.31%	-30.18%	-34.65%
TSHA Taysha Gene Therapies	0.00%	-0.86%	-16.88%	-29.10%	+45.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMCR Immunocore	2.58	Moderate Buy	$56.38	89.75% Upside
MYGN Myriad Genetics	1.75	Reduce	$3.93	-13.36% Downside
NTLA Intellia Therapeutics	2.35	Hold	$20.98	71.11% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	175.79% Upside

Current Analyst Ratings Breakdown

Latest MYGN, TSHA, NTLA, and IMCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $8.00
9/21/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/9/2026	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$6.00 ➝ $3.60
9/9/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
9/9/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/9/2026	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/3/2026	IMCR Immunocore	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/1/2026	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$5.45 ➝ $2.00
8/25/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMCR Immunocore	$400.02M	3.82	N/A	N/A	$7.52 per share	3.95
MYGN Myriad Genetics	$824.50M	0.53	$3.75 per share	1.21	$3.95 per share	1.15
NTLA Intellia Therapeutics	$67.67M	25.39	N/A	N/A	$5.80 per share	2.11
TSHA Taysha Gene Therapies	$9.77M	154.41	N/A	N/A	$0.90 per share	5.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMCR Immunocore	-$35.51M	-$0.37	N/A	118.84	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
MYGN Myriad Genetics	-$365.90M	-$1.19	N/A	N/A	N/A	-13.96%	-16.09%	-8.10%	11/2/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest MYGN, TSHA, NTLA, and IMCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
7/30/2026	Q2 2026	MYGN Myriad Genetics	-$0.0579	-$0.25	-$0.1921	-$0.46	$206.03 million	$190.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMCR Immunocore	0.94	4.47	4.44
MYGN Myriad Genetics	0.40	2.21	1.98
NTLA Intellia Therapeutics	N/A	6.65	6.65
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMCR Immunocore	84.50%
MYGN Myriad Genetics	99.02%
NTLA Intellia Therapeutics	88.77%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
IMCR Immunocore	10.10%
MYGN Myriad Genetics	1.90%
NTLA Intellia Therapeutics	3.50%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMCR Immunocore	524	51.50 million	46.30 million	Optionable
MYGN Myriad Genetics	2,700	95.65 million	93.83 million	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

MYGN, TSHA, NTLA, and IMCR Headlines

Recent News About These Companies

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2 at 8:00 AM | globenewswire.com

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

October 1 at 8:00 AM | globenewswire.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened

September 28, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

September 12, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7, 2026 | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MYGN, TSHA, NTLA, and IMCR Company Descriptions

Immunocore NASDAQ:IMCR

$29.71 -0.83 (-2.72%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$29.79 +0.08 (+0.27%)

As of 10/2/2026 07:30 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Myriad Genetics NASDAQ:MYGN

$4.54 +0.48 (+11.82%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.49 -0.05 (-1.15%)

As of 10/2/2026 07:59 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Intellia Therapeutics NASDAQ:NTLA

$12.26 +0.14 (+1.16%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$12.33 +0.07 (+0.57%)

As of 10/2/2026 07:46 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$4.63 -0.11 (-2.32%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.64 +0.01 (+0.32%)

As of 10/2/2026 07:30 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MYGN, TSHA, NTLA, and IMCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MYGN, TSHA, NTLA, and IMCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MYGN, TSHA, NTLA, and IMCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MYGN, TSHA, NTLA, and IMCR Company Descriptions

Immunocore NASDAQ:IMCR

Myriad Genetics NASDAQ:MYGN

Intellia Therapeutics NASDAQ:NTLA

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MYGN, TSHA, NTLA, and IMCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MYGN, TSHA, NTLA, and IMCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MYGN, TSHA, NTLA, and IMCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MYGN, TSHA, NTLA, and IMCR Company Descriptions

Immunocore NASDAQ:IMCR

Myriad Genetics NASDAQ:MYGN

Intellia Therapeutics NASDAQ:NTLA

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools